Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05350514 · ClinicalTrials.gov registry record
Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 14
- Enrollment target
NCT05350514: Completed study, sponsored by University of Colorado, Denver.
NCT05350514 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05350514 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The goal of the study is to characterize preclinical Alzheimer's Disease and related dementias (AD/ADRD) neuropathology in a selected group of young adults with youth-onset diabetes, and an age-similar group of young adults without diabetes.
Primary Outcome
Voxel-based morphometry via Sagittal 3D Accelerated MPRAGE/IRSPGR
Interventions
- DRUG PI-2620 tracer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2023-05-31 |
What the finished NCT05350514 record still lists
NCT05350514 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PI-2620 tracer is the first listed.
NCT05350514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05350514 about?
NCT05350514 is a clinical study titled "Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study". The goal of the study is to characterize preclinical Alzheimer's Disease and related dementias (AD/ADRD) neuropathology in a selected group of young adults with youth-onset diabetes, and an age-similar group of young adults without diabetes.
What is the current status of trial NCT05350514?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2022-07-19. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT05350514?
The interventions under investigation include: PI-2620 tracer (DRUG).
Who is sponsoring clinical trial NCT05350514?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy